Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 6/20 | 0.44 |
| ▸ | RARA | P10276 | 5/20 | 0.44 |
| ▸ | RARG | P13631 | 5/20 | 0.44 |
| ▸ | RXRA | P19793 | 2/20 | 0.42 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.42 |
| ▸ | CYP26B1 | Q9NR63 | 3/20 | 0.37 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | NR0B2 | Q15466 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4500268 | 1.00 | RARB (0.44) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL4500557 | 0.92 | RARB (0.46) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL4500556 | 0.92 | RARB (0.46) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL4494180 | 0.90 | RARB (0.44) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL4494185 | 0.90 | RARB (0.44) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL4508557 | 0.90 | RARB (0.44) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL4516963 | 0.88 | RARA (0.39) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL4516961 | 0.88 | RARA (0.39) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6247945 | 0.84 | RARB (0.47) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL4506863 | 0.82 | RARB (0.48) | RARBRARARARGRXRANR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348449-B2 | Ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-03-25 | — | — | US | claimed |
| EP-1565433-B1 | NOVEL LIGANDS THAT ARE ANTAGONISTS OF RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2007-03-14 | — | — | EP | claimed |
| US-20050234131-A1 | Novel ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-10-20 | — | — | US | claimed |
| US-7592478-B2 | Ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-09-22 | — | — | US | disclosed |
| US-20080213347-A1 | Novel ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. | 2008-09-04 | — | — | US | disclosed |
| US-7348449-B2 | Ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-03-25 | — | — | US | disclosed |
| EP-1565433-B1 | NOVEL LIGANDS THAT ARE ANTAGONISTS OF RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2007-03-14 | — | — | EP | disclosed |
| US-20050234131-A1 | Novel ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234131-A1 | Novel ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | RARB, RARG, RARA | RARB 1/4885RARA 3/4885RARG 2/4885 |
| US-20080213347-A1 | Novel ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | RARB, RARG, RARA | RARB 1/4885RARA 3/4885RARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.